Literature DB >> 9416844

Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.

J F Flores1, P M Pollock, G J Walker, J M Glendening, A H Lin, J M Palmer, M K Walters, N K Hayward, J W Fountain.   

Abstract

Germline mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identified in a proportion of melanoma kindreds. In the case of CDK4, only one specific mutation, resulting in the substitution of a cysteine for an arginine at codon 24 (R24C), has been found to be associated with melanoma. We have previously reported the identification of germline CDKN2A mutations in 7/18 Australian melanoma kindreds and the absence of the R24C CDK4 mutation in 21 families lacking evidence of a CDKN2A mutation. The current study represents an expansion of these efforts and includes a total of 48 melanoma families from Australia. All of these families have now been screened for mutations within CDKN2A and CDK4, as well as for mutations within the CDKN2A homolog and 9p21 neighbor, the CDKN2B gene, and the alternative exon 1 (E1beta) of CDKN2A. Families lacking CDKN2A mutations, but positive for a polymorphism(s) within this gene, were further evaluated to determine if their disease was associated with transcriptional silencing of one CDKN2A allele. Overall, CDKN2A mutations were detected in 3/30 (10%) of the new kindreds. Two of these mutations have been observed previously: a 24 bp duplication at the 5' end of the gene and a G to C transversion in exon 2 resulting in an M531 substitution. A novel G to A transition in exon 2, resulting in a D108N substitution was also detected. Combined with our previous findings, we have now detected germline CDKN2A mutations in 10/48 (21%) of our melanoma kindreds. In none of the 'CDKN2A-negative' families was melanoma found to segregate with either an untranscribed CDKN2A allele, an R24C CDK4 mutation, a CDKN2B mutation, or an E1beta mutation. The last three observations suggest that these other cell cycle control genes (or alternative gene products) are either not involved at all, or to any great extent, in melanoma predisposition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416844     DOI: 10.1038/sj.onc.1201470

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

2.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

4.  MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations.

Authors:  N F Box; D L Duffy; W Chen; M Stark; N G Martin; R A Sturm; N K Hayward
Journal:  Am J Hum Genet       Date:  2001-08-08       Impact factor: 11.025

5.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

Review 6.  New developments in melanoma genetics.

Authors:  N Hayward
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

Review 7.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

8.  Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Authors:  Keith Nykamp; Michael Anderson; Martin Powers; John Garcia; Blanca Herrera; Yuan-Yuan Ho; Yuya Kobayashi; Nila Patil; Janita Thusberg; Marjorie Westbrook; Scott Topper
Journal:  Genet Med       Date:  2017-05-11       Impact factor: 8.822

9.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Survival from melanoma of the skin in England and Wales up to 2001.

Authors:  C H Ottensmeier; M Gore
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.